Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30424935 | 0.74 | ALDH1A1 (0.50) | MIFALDH1A1KDM4EGAAMAPT | |
| SCHEMBL3215853 | 0.73 | HTT (0.42) | ALDH1A1LMNASMN1; SMN2HTTATM | |
| SCHEMBL9747476 | 0.71 | CYP11B1 (0.66) | MAPTPOLB | |
| SCHEMBL29630801 | 0.70 | L3MBTL1 (0.50) | MIFALDH1A1KDM4EGAAMAPT | |
| SCHEMBL29630587 | 0.70 | KDM4E (0.47) | MIFALDH1A1KDM4EGAAMAPT | |
| SCHEMBL43367 | 0.70 | MIF (0.62) | MIFALDH1A1KDM4EGAAMAPT | |
| SCHEMBL1008752 | 0.69 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAAMAPTLMNA | |
| Bromide SCHEMBL2192405 | 0.68 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAAMAPTLMNA | |
| SCHEMBL5103155 | 0.66 | TAAR1 (0.64) | MIFALDH1A1KDM4EGAAMAPT | |
| SCHEMBL3237564 | 0.66 | TAAR1 (0.64) | MIFALDH1A1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035924-A1 | NOVEL 4-AMINO-PYRIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-02-11 | — | — | US | claimed |
| US-20100035924-A1 | NOVEL 4-AMINO-PYRIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035924-A1 | NOVEL 4-AMINO-PYRIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNN1, KCNN2, KCNN3 | MIF 4783/4885ALDH1A1 4188/4885KDM4E 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.